All posts by Alzforum, Gabrielle Strobel

FTD Study Group 2016: Regulators Tell Frontotemporal Dementia Community: We Play on Your Team

As no drugs are approved to treat FTD, none have undergone a formal regulatory process. No framework exists to guide the various drug development programs that are sprouting up across the United States and Europe. At the FTD Study Group, participants asked how should we develop therapies for the rare and heterogeneous set of diseases that make up frontotemporal dementia?

Read more »


Frontotemporal Dementia (FTD) Study Group Workshop: Building an Infrastructure to Support FTLD Therapeutic Development

Earlier this month in Washington, D.C., 95 scientists from 23 companies, 19 academic institutions and two regulatory agencies met with funders, advocates and patients and caregivers. The buzz was all about learning from the mistakes and setbacks of drug development in Alzheimer’s disease and getting a collective act together while the FTD field is still young. Read coverage brought to you through our partnership with Alzforum.

Read more »


ICFTD 2014: Meet the Artful Leftie: NIH Jump-Starts U.S.-Canadian FTLD Cohorts

This article is Part 4 of a 9-part series on the International Conference on Frontotemporal Dementias. To read the full conference coverage, click here.  On October 23, on the day the 9th International Conference on Frontotemporal Dementia got underway in Vancouver, Canada, the National Institutes of Health released news of three five-year grants totaling $5.9 […]

Read more »


ICFTD 2014: German Network of 700 FTLD Patients Presents Baseline Data

This article is Part 3 of a 9-part series on the International Conference on Frontotemporal Dementias. To read the full conference coverage, click here.  An 11-center consortium of clinical centers in Germany has enrolled 700 patients with symptomatic frontotemporal lobar degeneration (FTLD), most at early stages of disease, plus 10 presymptomatic at-risk relatives. Coordinated by Markus […]

Read more »


ICFTD 2014: First Data from GENFI1: Brain’s Insula Region Shrinks A Decade Before FTD

This article is Part 2 of a 9-part series on the International Conference on Frontotemporal Dementias. To read the full conference coverage, click here.  At the 9th International Conference on Frontotemporal Dementia (ICFTD), held October 23 to 25 in Vancouver, British Columbia, Canada, the biggest news splash happened when the first international cohort study of […]

Read more »


ICFTD 2014: Vancouver Frontotemporal Dementia Conference Shows Awakening Field

This article is Part 1 of a 9-part series on the International Conference on Frontotemporal Dementias. To read the full conference coverage, click here.  It can start with insensitive comments at the dinner table. It can start with theft by a previously law-abiding citizen, or sexual misconduct by a hitherto faithful spouse. It can start with […]

Read more »


AD/PD 2013: Human-Derived SOD1 Antibodies Show Promise in ALS Mice

You could say the concept that endogenous proteins in the body can misfold, aggregate, and spread disease from cell to cell has created infectious enthusiasm for drug development across the field of neurodegeneration and beyond. After all, a pathogenic protein that leaves one cell and passes through intercellular space before slipping into another ought to […]

Read more »


Human-Derived SOD1 Antibodies Show Promise in ALS Mice

You could say the concept that endogenous proteins in the body can misfold, aggregate, and spread disease from cell to cell has created infectious enthusiasm for drug development across the field of neurodegeneration and beyond. After all, a pathogenic protein that leaves one cell and passes through intercellular space before slipping into another ought to […]

Read more »